Anti-Tumour Activity of Arylbismuth(III) Oxine Complexes
Author Information
Author(s): Katharine A. Smith, Glen B. Deacon, W. Roy Jackson, Edward R.T. Tiekink, Silvina Rainone, Lorraine K. Webster
Primary Institution: Monash University
Hypothesis
Can new arylbismuth(III) oxinates exhibit anti-tumour activity comparable to or better than cisplatin?
Conclusion
The new arylbismuth(III) oxinates showed high in vitro biological activity against certain cancer cell lines, but limited in vivo activity.
Supporting Evidence
- The new arylbismuth(III) oxinates showed comparable or better activity than cisplatin against L1210 leukaemia cells.
- Initial in vivo testing against a solid mouse plasmacytoma and P388 leukaemia revealed no significant activity.
- Most compounds demonstrated excellent in vitro activity compared to cisplatin.
Takeaway
Scientists made new compounds from bismuth that might help fight cancer, but they didn't work as well in living mice.
Methodology
The study involved synthesizing arylbismuth(III) oxinates and testing their anti-cancer activity in vitro and in vivo.
Limitations
The in vivo tests showed no significant activity, possibly due to delivery issues of the compounds.
Want to read the original?
Access the complete publication on the publisher's website